Pharma Contract Sales Outlook 2025–2030: Multilingual Teams Drive Global Expansion
The Pharma Data
JUNE 6, 2025
As pharma companies grapple with mounting pressure from regulators, payers, and evolving market dynamics, the CSO model offers a compelling alternative to traditional, fully in-house sales forces. Biosimilars and Generics : Where cost competition necessitates strategic brand differentiation and efficient coverage.
Let's personalize your content